News & Updates

Show Multimedia Only

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025 by

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic, progressive disorder associated with adverse outcomes in advanced stages. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts discussed recommendations in the American Heart Association’s (AHA) presidential advisory on CKM health, strategies for early CKM intervention in primary care, as well as guideline recommendations and clinical trial results supporting the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i; eg, empagliflozin) in CKM syndrome.

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025

GLP-1 drugs can raise testosterone levels in men

19 Aug 2025 by

The use of glucagon-like peptide 1 (GLP-1) drugs such as semaglutide, dulaglutide, and the dual agonist tirzepatide helps boost testosterone levels in men with obesity and type 2 diabetes (T2D), according to new research.

GLP-1 drugs can raise testosterone levels in men

19 Aug 2025

Combo therapy enhances fat loss while preserving lean mass

19 Aug 2025 by

Bimagrumab, when combined with semaglutide, enhances weight loss while preserving lean mass better than either treatment alone in the phase IIb BELIEVE study presented at ADA 2025.

Combo therapy enhances fat loss while preserving lean mass

19 Aug 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

18 Aug 2025 by

New research suggests that in older adults with type 2 diabetes (T2D) who are taking metformin, using dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) has a null effect on the risk of COVID-19 infection. However, among those who do contract the virus, the use of these drugs appears to lower the risk of hospitalization.

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

18 Aug 2025

Intermittent energy restriction stands out for improving outcomes in people with T2D, obesity

17 Aug 2025 by

In individuals with type 2 diabetes (T2D) and obesity, an intermittent energy restriction (IER) diet helps with glucose control, with the advantage of improving insulin sensitivity, reducing triglycerides, and being easier to follow compared with other dietary interventions, as shown in a single-centre randomized controlled trial.

Intermittent energy restriction stands out for improving outcomes in people with T2D, obesity

17 Aug 2025

Unhealthy weight in parents before pregnancy tied to adverse birth outcomes

17 Aug 2025

The preconception weight of parents, whether too low or too high, contributes to the risk of adverse birth outcomes, including perinatal death and birth defects, according to a study.

Unhealthy weight in parents before pregnancy tied to adverse birth outcomes

17 Aug 2025

Advancing collaboration in COVID-19 care

16 Aug 2025

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

16 Aug 2025

Diet influences menarche timing

15 Aug 2025 by

Menarche appears to occur later for girls with good diet quality, regardless of BMI and height, as shown in a US cohort study.

Diet influences menarche timing

15 Aug 2025

Periconceptional GLP-1RA exposure safety varies on indication for use

11 Aug 2025 by

Exposure to glucagon-like peptide 1 receptor agonists (GLP-1RAs) during pregnancy poses a modest increase in the risk of preterm birth in the context of diabetes treatment, but there is no evidence of increased obstetric complications when the drugs are exclusively used for weight management, according to new research.

Periconceptional GLP-1RA exposure safety varies on indication for use

11 Aug 2025

News & Updates

Showing Endocrinology articles

Showing

Specialty:

CKM syndrome: Strategies for early intervention in primary care

CKM syndrome: Strategies for early intervention in primary care

GLP-1 drugs can raise testosterone levels in men

GLP-1 drugs can raise testosterone levels in men

Combo therapy enhances fat loss while preserving lean mass

Combo therapy enhances fat loss while preserving lean mass

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

Intermittent energy restriction stands out for improving outcomes in people with T2D, obesity

Intermittent energy restriction stands out for improving outcomes in people with T2D, obesity

Unhealthy weight in parents before pregnancy tied to adverse birth outcomes

Unhealthy weight in parents before pregnancy tied to adverse birth outcomes

Advancing collaboration in COVID-19 care

Advancing collaboration in COVID-19 care

Diet influences menarche timing

Diet influences menarche timing

Periconceptional GLP-1RA exposure safety varies on indication for use

Periconceptional GLP-1RA exposure safety varies on indication for use